A Phase I/IIa Study Assessing Single and Multiple Doses of Hepatitis C Virus (HCV) Protease Inhibitor IDX320 in Healthy and Genotype 1 HCV-Infected Subjects.
Phase of Trial: Phase I/II
Latest Information Update: 27 Mar 2012
At a glance
- Drugs IDX 320 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 26 Oct 2011 Results will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2011)
- 01 Nov 2010 Results were presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases.
- 07 Sep 2010 Status changed from recruiting to completed. According to an Idenix media release, all planned studies of IDX 320 to date have been completed and there are currently no healthy volunteers or patients receiving this drug.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History